Cargando…
Retraction Note: Analysis of antiviral efficacy after switching from brand to generic entecavir in patients with treatment-naïve chronic hepatitis B
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9419311/ https://www.ncbi.nlm.nih.gov/pubmed/36028816 http://dx.doi.org/10.1186/s12876-022-02483-8 |
| _version_ | 1784777148814327808 |
|---|---|
| author | Hsu, Po-Ke Su, Pei-Yuan Wu, Chia-Lin |
| author_facet | Hsu, Po-Ke Su, Pei-Yuan Wu, Chia-Lin |
| author_sort | Hsu, Po-Ke |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9419311 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94193112022-08-28 Retraction Note: Analysis of antiviral efficacy after switching from brand to generic entecavir in patients with treatment-naïve chronic hepatitis B Hsu, Po-Ke Su, Pei-Yuan Wu, Chia-Lin BMC Gastroenterol Retraction Note BioMed Central 2022-08-26 /pmc/articles/PMC9419311/ /pubmed/36028816 http://dx.doi.org/10.1186/s12876-022-02483-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Retraction Note Hsu, Po-Ke Su, Pei-Yuan Wu, Chia-Lin Retraction Note: Analysis of antiviral efficacy after switching from brand to generic entecavir in patients with treatment-naïve chronic hepatitis B |
| title | Retraction Note: Analysis of antiviral efficacy after switching from brand to generic entecavir in patients with treatment-naïve chronic hepatitis B |
| title_full | Retraction Note: Analysis of antiviral efficacy after switching from brand to generic entecavir in patients with treatment-naïve chronic hepatitis B |
| title_fullStr | Retraction Note: Analysis of antiviral efficacy after switching from brand to generic entecavir in patients with treatment-naïve chronic hepatitis B |
| title_full_unstemmed | Retraction Note: Analysis of antiviral efficacy after switching from brand to generic entecavir in patients with treatment-naïve chronic hepatitis B |
| title_short | Retraction Note: Analysis of antiviral efficacy after switching from brand to generic entecavir in patients with treatment-naïve chronic hepatitis B |
| title_sort | retraction note: analysis of antiviral efficacy after switching from brand to generic entecavir in patients with treatment-naïve chronic hepatitis b |
| topic | Retraction Note |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9419311/ https://www.ncbi.nlm.nih.gov/pubmed/36028816 http://dx.doi.org/10.1186/s12876-022-02483-8 |
| work_keys_str_mv | AT hsupoke retractionnoteanalysisofantiviralefficacyafterswitchingfrombrandtogenericentecavirinpatientswithtreatmentnaivechronichepatitisb AT supeiyuan retractionnoteanalysisofantiviralefficacyafterswitchingfrombrandtogenericentecavirinpatientswithtreatmentnaivechronichepatitisb AT wuchialin retractionnoteanalysisofantiviralefficacyafterswitchingfrombrandtogenericentecavirinpatientswithtreatmentnaivechronichepatitisb |